Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
accepted:
23
06
2020
pubmed:
1
7
2020
medline:
4
6
2021
entrez:
1
7
2020
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic inflammatory disease. The HS core outcome set calls for a patient global assessment (PtGA). To assess the validity, reliability and responsiveness of a candidate single-item PtGA for HS-specific health-related quality of life (HRQoL). Cognitive debriefing interviews were conducted with patients with HS in Denmark and the USA. A cross-sectional observational study was done with adults with HS in the USA and Denmark. Candidate PtGA item, demographic items and multiple patient-reported scales - the Hidradenitis Suppurativa Quality of Life (HiSQOL), Dermatology Life Quality Index (DLQI) and numerical rating scale (NRS) for pain - were concurrently administered to evaluate convergent and known-groups validity. Scales with a single-item assessment of change were readministered 24-72 h later, to evaluate reliability and responsiveness. After cognitive debriefing, the candidate PtGA for HS-specific HRQoL was finalized with five response levels. Convergent validity of the PtGA was supported by significant correlations with HiSQOL score [r = 0·79, 95% confidence interval (CI) 0·75-0·82] and DLQI (r = 0·78, 95% CI 0·74-0·82). The PtGA displayed known-groups validity with DLQI score bands based on significance of an anova (P < 0·001). Good test-retest reliability was supported by the intraclass correlation coefficient (0·82, 95% CI 0·78-0·85) for those who reported stable HS. Responsiveness was assessed by differences in PtGA score against a patient-reported assessment of change, which showed significant differences towards improvement. The single-item PtGA exhibits reliability, validity and responsiveness in assessing HS-specific HRQoL in HS, making it a good provisional tool for HS clinical research.
Sections du résumé
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic inflammatory disease. The HS core outcome set calls for a patient global assessment (PtGA).
OBJECTIVES
To assess the validity, reliability and responsiveness of a candidate single-item PtGA for HS-specific health-related quality of life (HRQoL).
METHODS
Cognitive debriefing interviews were conducted with patients with HS in Denmark and the USA. A cross-sectional observational study was done with adults with HS in the USA and Denmark. Candidate PtGA item, demographic items and multiple patient-reported scales - the Hidradenitis Suppurativa Quality of Life (HiSQOL), Dermatology Life Quality Index (DLQI) and numerical rating scale (NRS) for pain - were concurrently administered to evaluate convergent and known-groups validity. Scales with a single-item assessment of change were readministered 24-72 h later, to evaluate reliability and responsiveness.
RESULTS
After cognitive debriefing, the candidate PtGA for HS-specific HRQoL was finalized with five response levels. Convergent validity of the PtGA was supported by significant correlations with HiSQOL score [r = 0·79, 95% confidence interval (CI) 0·75-0·82] and DLQI (r = 0·78, 95% CI 0·74-0·82). The PtGA displayed known-groups validity with DLQI score bands based on significance of an anova (P < 0·001). Good test-retest reliability was supported by the intraclass correlation coefficient (0·82, 95% CI 0·78-0·85) for those who reported stable HS. Responsiveness was assessed by differences in PtGA score against a patient-reported assessment of change, which showed significant differences towards improvement.
CONCLUSIONS
The single-item PtGA exhibits reliability, validity and responsiveness in assessing HS-specific HRQoL in HS, making it a good provisional tool for HS clinical research.
Identifiants
pubmed: 32602129
doi: 10.1111/bjd.19344
pmc: PMC7887568
mid: NIHMS1620518
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-687Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Organisme : AHRQ HHS
ID : K08 HS024585
Pays : United States
Organisme : NIAMS NIH HHS
ID : L30 AR072438
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000127
Pays : United States
Organisme : Health and Care Research Wales
Informations de copyright
© 2020 British Association of Dermatologists.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Investig Dermatol Symp Proc. 2004 Mar;9(2):169-80
pubmed: 15083785
Musculoskeletal Care. 2013 Dec;11(4):229-37
pubmed: 23378146
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
Br J Dermatol. 2018 Mar;178(3):715-721
pubmed: 29080368
Br J Dermatol. 2008 Nov;159(5):997-1035
pubmed: 18795920
Arthritis Res Ther. 2016 Oct 28;18(1):251
pubmed: 27793211
Br J Dermatol. 2018 Sep;179(3):642-650
pubmed: 29654696
Br Med J (Clin Res Ed). 1986 Feb 1;292(6516):344
pubmed: 3080166
J Pain Symptom Manage. 2011 Jun;41(6):1073-93
pubmed: 21621130
N Engl J Med. 2012 Jan 12;366(2):158-64
pubmed: 22236226
JAMA Dermatol. 2015 Apr;151(4):375-81
pubmed: 25549367
J Invest Dermatol. 2005 Oct;125(4):659-64
pubmed: 16185263
BMJ Open. 2017 Feb 20;7(2):e014733
pubmed: 28219961
Br J Dermatol. 2020 Aug;183(2):340-348
pubmed: 31705538
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571